Assay Report
Methods · Standard Curves · QC · Results
Ultra-sensitive single-molecule digital immunoassay services for quantifying total alpha-synuclein (α-Syn), oligomeric aggregates, and phosphorylated proteoforms in plasma, serum, cerebrospinal fluid (CSF), neuron-derived extracellular vesicles (NDEVs), and brain tissue lysates down to sub-picogram per milliliter detection limits.
As the primary pathophysiological hallmark of Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), circulating alpha-synuclein provides an objective fluid biomarker readout for preclinical neurodegenerative drug pipelines and synucleinopathy disease models.
Establishing standardized bioanalytical parameters to ensure high data integrity across dynamic synuclein aggregate cascades.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Epitope & Conformation Strategy | Total α-Syn vs. oligomer-specific vs. pS129 phosphorylated proteoforms | Selects the precise species sensitive to your therapeutic mechanism of action (e.g., aggregation inhibition vs. clearance). |
| Hemolysis Monitoring & Triage | Measuring free hemoglobin (Hb <500 ng/mL) and optical absorbance (A414 nm) | Prevents false-positive signal inflation caused by erythrocyte alpha-synuclein lysis in blood samples. |
| Matrix & Exosome Isolation | Total plasma/serum vs. CSF vs. neuron-derived extracellular vesicle (NDEV) cargo | Isolates central pathogenic signatures from systemic background biofluids. |
| Micro-Volume Serial Allocation | 15 μL net volume per well, duplicate verification reserve, and orthogonal follow-up | Conserves longitudinal small-animal biofluids across multi-month preclinical dosing regimens. |
| Plate Layout & Balancing | Randomizing transgenic cohorts, drug doses, and longitudinal timepoints across runs | Eliminates confounding between true experimental treatment effects and run-to-run bioanalytical variance. |
Validated single-analyte and multiplex digital immunoassay configurations for ultra-sensitive alpha-synuclein bioanalysis.
| Assay Target | Target Molecule Specificity | Functional LLOQ (pg/mL) | Dynamic Range (pg/mL) | Primary Research Focus |
|---|---|---|---|---|
| Total Alpha-Synuclein | Full-length monomeric and soluble α-Syn | 0.020 | 0.020 – 1,000 | Baseline synuclein levels in CSF, NDEV cargo, and preclinical transgenic models (A53T, A30P) |
| Phospho-Ser129 α-Syn (pS129) | Pathological hyperphosphorylated α-Syn | 0.050 | 0.050 – 500 | Lewy body-associated aggregate tracking, kinase inhibitor efficacy (PLK2/CK2), post-mortem brain tissue |
| Neuron-Derived Exosomal α-Syn | L1CAM+ immunocaptured NDEV cargo | 0.010 | 0.010 – 200 | Blood-based liquid biopsy for central Lewy body pathology, eliminating erythrocyte background |
| Multi-Marker Neuro Panel Integration | α-Syn + Simoa NfL + GFAP (glial fibrillary acidic protein) + UCH-L1 (ubiquitin C-terminal hydrolase L1) | 0.050 – 1.80 | 0.050 – 2,000 | Multi-pathway profiling: synucleinopathy (α-Syn) + axonal loss (NfL) + astrogliosis (GFAP) in PD/MSA |
Evaluating analytical sensitivity, matrix tolerance, sample consumption, and detection boundaries across bioanalytical platforms.
| Technical Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa HD-X |
|---|---|---|---|---|
| Analytical Sensitivity (LLOQ) | 20.0 – 100.0 pg/mL | 5.0 – 20.0 pg/mL | 1.0 – 10.0 pg/mL | 0.010 – 0.050 pg/mL (Sub-pg/mL) |
| Basal Blood Detectability | <20% (Severe dropout) | 40% – 60% | 60% – 80% (CSF optimal; plasma variable) | 100% Quantifiable across all cohorts |
| Sample Consumption per Test | 50 – 100 μL (Neat) | 25 – 50 μL | 25 – 50 μL | 15 μL net volume (1:4 dilution) |
| Exosomal NDEV Sensitivity | Inadequate (Low cargo yield) | Low | Moderate | Excellent (Quantifies low exosomal cargo) |
| Linear Dynamic Range | 2.0 logs | 3.0 – 3.5 logs | 3.5 – 4.0 logs | >4.5 logs (Poisson digital + Analog) |
| Serial Rodent Survival Bleeds | Poor (Requires terminal pooling) | Moderate | Moderate | Excellent (Serial tail-vein / submandibular) |
| Primary Matrix Fit | High-titer in vitro recombinant | Broad discovery screening | CSF, brain tissue homogenates | Plasma, serum, CSF, NDEV exosomes |
Cross-platform transitions from legacy plate ELISA, Luminex, or MSD systems to digital Simoa require structured bioanalytical method bridging. Differences in antibody clone affinities, synthetic calibrator constructs, incubation kinetics, and matrix dilution factors commonly generate numerical shifts in absolute values, even when inter-platform rank correlations exceed r = 0.95.
Our Bridging Protocol: We test a representative pilot subset (15–20 paired baseline and elevated research specimens) in parallel across both platforms to establish a validated mathematical conversion equation, ensuring longitudinal dataset continuity across multi-year drug discovery campaigns.
Bioanalytical parameters established according to rigorous fit-for-purpose biomarker validation guidelines.
Rigorous pre-analytical optical absorbance screening (A414 nm & free Hb <500 ng/mL) eliminates false-positive contamination caused by erythrocyte alpha-synuclein lysis.
Homotypic sandwich assay configuration selectively captures pathological multi-epitope aggregates and fibrils while ignoring physiological monomeric background.
Immuno-magnetic isolation targeting neuronal surface markers (L1CAM / NCAM) confirms central origin and eliminates peripheral matrix interference.
Barcode verification on dry ice, spectrophotometric A414 nm hemoglobin assessment, cataloged into monitored -80°C biobanking.
Automated liquid handling performs 1:4 dilution in matrix-matched diluent supplemented with heterophilic blocking agents.
Capture antibodies covalently coated on paramagnetic beads bind target alpha-synuclein, followed by biotinylated detector binding and SBG enzyme labeling.
Bead-enzyme complexes are loaded into 216,000 microwells on Simoa discs, oil-sealed, and imaged for digital Poisson enzyme counting (AEB).
Software algorithms interpolate AEB values against calibration curves to output absolute pg/mL concentrations, replicate statistics, and QC metrics.
Standardized pre-analytical protocols ensuring alpha-synuclein stability and eliminating erythrocyte-derived background contamination.
| Pre-Analytical Parameter | Why It Matters for Alpha-Synuclein Bioanalysis | Intake Specification & Recommendation |
|---|---|---|
| Hemolysis Control & Triage | Red blood cell lysis releases massive quantities of erythrocyte α-Syn, artificially inflating plasma values by 10- to 100-fold. | Visually inspect and measure free hemoglobin; hemolyzed samples (Hb >500 ng/mL or A414 >0.2) should be excluded or triaged. |
| Anticoagulant Selection | Heparin causes polyanionic interference; K2-EDTA prevents platelet activation and maintains sample stability. | K2-EDTA plasma is strongly preferred; collection tubes must be mixed gently (invert 8–10 times) without vortexing. |
| Centrifugation Protocol | Rapid separation prevents in vitro erythrocyte leakage and platelet degranulation. | Centrifuge at 2,000 × g for 15 min at 4°C within 60 minutes of collection; harvest platelet-poor plasma. |
| Freeze-Thaw Management | Repeated freeze-thaw cycles promote artificial in vitro oligomerization and epitope degradation. | Aliquot immediately into polypropylene cryovials; store at -80°C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Single-molecule digital counting requires minimal specimen input, conserving small-animal biofluids. | 15 μL net volume per well (30–50 μL recommended for duplicate verification and reserve). |
Applying ultra-sensitive single-molecule alpha-synuclein measurements across disease modeling and therapeutics evaluation.
Track progressive synuclein accumulation and oligomeric spread across familial PD transgenic mouse and rat lines.
Measure local and spreading synuclein pathology following stereotaxic intracerebral injection of recombinant alpha-synuclein PFFs.
Quantify target engagement and dose-dependent protein reduction following anti-sense oligonucleotide therapeutic delivery.
Quantify differential oligomeric synuclein burdens in CSF and NDEVs across preclinical synucleinopathy cohorts.
Measure clearance kinetics of pathological Ser129-phosphorylated aggregates following targeted protein degrader administration.
Track synuclein trajectories in surviving rodent cohorts via 15 μL serial tail-vein draws over multi-month dosing studies.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Landmark peer-reviewed studies establishing sub-picogram alpha-synuclein quantification and exosomal bioanalysis.
Study Design Takeaway: Establishes sub-picogram analytical sensitivity for alpha-synuclein in human biofluids and demonstrates strict hemolysis cut-offs to prevent false-positive contamination.
Study Design Takeaway: Demonstrates that immunocapturing CNS-derived L1CAM+ exosomes in peripheral blood isolates central synuclein pathology from peripheral erythrocyte background.
Study Design Takeaway: Validates the quantitative relationship between cerebrospinal fluid alpha-synuclein depletion/aggregation and Lewy body disease progression.
Study Design Takeaway: Validates the automated engineering and single-molecule accuracy of dye-encoded magnetic beads in digital immunoassay bioanalysis.
Addressing common bioanalytical and project planning inquiries.
Red blood cells contain over 99% of total blood alpha-synuclein (concentrations up to 1,000-fold higher than normal plasma). Even minor in vitro erythrocyte lysis during blood collection can release intracellular alpha-synuclein, causing massive false-positive signal elevation. We perform spectrophotometric hemoglobin screening (A414 nm) on all blood specimens to ensure data integrity.
Yes. Using conformation-specific antibody pairs or homotypic sandwich configurations (where identical monoclonal antibodies are used for both capture and detection), Simoa selectively binds multi-epitope oligomers while ignoring single monomeric molecules.
Neuron-derived exosomes (isolated via neural surface markers such as L1CAM) cross the blood-brain barrier into peripheral blood. Measuring alpha-synuclein inside these purified neuronal vesicles provides a pristine snapshot of central nervous system Lewy body pathology while completely eliminating peripheral red blood cell background.
Yes. Our Simoa alpha-synuclein assays cross-react robustly with both human and rodent alpha-synuclein, making them ideally suited for transgenic models (e.g., A53T, A30P, Thy1-aSyn) and preformed fibril (PFF) seeding models.
Cross-platform comparisons should be treated as a formal method bridging exercise. While relative group rankings and fold-changes correlate strongly (r > 0.95), variations in calibrator constructs, antibody affinities, and dilution factors introduce minor numerical offsets. We provide paired bridging studies to establish mathematical conversion algorithms for long-term programs.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical drug discovery, animal disease models, translational research cohorts, and in vitro cellular characterization, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×